Special Issue "Pharmacogenomics: Precision Medicine and Drug Response"

A special issue of Genes (ISSN 2073-4425). This special issue belongs to the section "Molecular Genetics and Genomics".

Deadline for manuscript submissions: 10 January 2022.

Special Issue Editor

Prof. Dr. Emiliano Giardina
E-Mail Website
Guest Editor
1. Genomic Medicine Laboratory UILDM, Santa Lucia Foundation, 00142 Rome, Italy
2. Forensic Genetics Laboratoty, Department of Biomedicine and Prevention, Tor Vergata University, 00133 Rome, Italy
Interests: forensic genetics; genetic counselling; human identification; neurogenetics; prenatal and postnatal genetic diagnosis; pharmacogenetics, genetics of complex diseases
Special Issues and Collections in MDPI journals

Special Issue Information

Dear Colleagues,

The advances in disease treatment have allowed the development of new therapeutic approaches. Over the years, many therapies have shown different efficacy profiles, supporting the development of precision medicine. Several pharmacogenomic approaches have been used to individualize treatments, optimizing dosage and preventing adverse effects. With the recent development of new high-throughput technologies and massive parallel sequencing, it is now possible to test the entire human genome to reveal positive associations between specific variations and the response to drugs in terms of efficacy and safety. Although numerous associations have been published, the translation to clinical practice in some areas has been minimal. A notable exception to this is the oncological field.

This Special Issue aims to curate available practical information in the pharmacogenomic domain to promote the translation of research data into precision medical protocols. Particular attention will be paid to new bioinformatic approaches to the interpretation of omic data and to research advances in populations that up to this point have little study data. At the same time, drug repurposing approaches will be encouraged to promote alternative applications of drugs with existing approval for use. This Special Issue of Genes will highlight recent advances in the field, and innovations in the use of omic data in the treatment of human diseases. Clinical and molecular studies, as well as reviews, will be considered for publication in this Issue. 

Prof. Dr. Emiliano Giardina
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Genes is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Pharmacogenomics
  • Drug Repurposing
  • Precision Medicine
  • Drug response
  • Personalized therapies

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Review

Article
Tumor-Associated Macrophage Promotes the Survival of Cancer Cells upon Docetaxel Chemotherapy via the CSF1/CSF1R–CXCL12/CXCR4 Axis in Castration-Resistant Prostate Cancer
Genes 2021, 12(5), 773; https://doi.org/10.3390/genes12050773 - 19 May 2021
Cited by 1 | Viewed by 582
Abstract
Castration-resistant prostate cancer (CRPC) is an advanced stage of prostate cancer that can progress rapidly even in patients treated with castration. Previously, we found that tumor-associated macrophages (TAM) can be recruited by CSF-1 secreted by docetaxel-treated prostate cancer cells and promote the survival [...] Read more.
Castration-resistant prostate cancer (CRPC) is an advanced stage of prostate cancer that can progress rapidly even in patients treated with castration. Previously, we found that tumor-associated macrophages (TAM) can be recruited by CSF-1 secreted by docetaxel-treated prostate cancer cells and promote the survival of cancer cells in response to chemotherapy. The inhibition of CSF-1R can impede this effect and significantly prolong survival in xenograft mice. However, the actual mechanism of how TAM improves cancer cell survival still remains elusive and controversial. Here, for the first time, we found that the enhanced survival of cancer cells achieved by TAM was mainly mediated by CXCR4 activation from the increased secretion of CXCL12 from CSF-1 activated TAM. This finding helps to clarify the mechanism of chemoresistance for second-line chemotherapy using docetaxel, facilitating the development of novel drugs to overcome immune tolerance in castration-resistant prostate cancer. Full article
(This article belongs to the Special Issue Pharmacogenomics: Precision Medicine and Drug Response)
Show Figures

Graphical abstract

Review

Jump to: Research

Review
Pharmacogenomics: An Update on Biologics and Small-Molecule Drugs in the Treatment of Psoriasis
Genes 2021, 12(9), 1398; https://doi.org/10.3390/genes12091398 - 10 Sep 2021
Viewed by 222
Abstract
Pharmacogenomic studies allowed the reasons behind the different responses to treatments to be understood. Its clinical utility, in fact, is demonstrated by the reduction in adverse drug reaction incidence and the improvement of drug efficacy. Pharmacogenomics is an important tool that is able [...] Read more.
Pharmacogenomic studies allowed the reasons behind the different responses to treatments to be understood. Its clinical utility, in fact, is demonstrated by the reduction in adverse drug reaction incidence and the improvement of drug efficacy. Pharmacogenomics is an important tool that is able to improve the drug therapy of different disorders. In particular, this review will highlight the current pharmacogenomics knowledge about biologics and small-molecule treatments for psoriasis. To date, studies performed on genes involved in the metabolism of biological drugs (tumor necrosis factor inhibitors and cytokines inhibitors) and small molecules (apremilast, dimethyl fumarate, and tofacitinib) have provided conflicting results, and further investigations are necessary in order to establish a set of biomarkers to be introduced into clinical practice. Full article
(This article belongs to the Special Issue Pharmacogenomics: Precision Medicine and Drug Response)
Back to TopTop